retatrutide trials results 💉 may be redefining obesity treatment. New data from TRIUMPH-1 Trial showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Lilly's retatrutide delivers promising results

Those who continued the medication lost an additional 5.5%, meaning the difference between continuing and stopping was nearly 20 percentage points

Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke

Outside of diabetes and obesity care, Novo Nordisks other core segment, Rare Disease , contributes about 6% of total revenue

However, surgery is not without risks and requires life-long lifestyle commitments, as well as vitamin supplementation to manage vitamin deficiencies that can occur

Protein intake becomes even more critical during tapering because protein is the most satiating macronutrient, meaning it keeps you fuller longer

ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning